GET THE APP

Cancer Science and Pediatrics 2019: Newborns with hypoxic ischemic encephalopathy treated with hypothermia therapy using neonatal laminar flow unit - Jose M. R. Perez - Maternidade Sao Miguel, Casa de Saude de Guarulhos, Brazil. | Abstract

Pediatric Oncology: Open Access

Abstract

Indexed In
  • Genamics JournalSeek
  • Directory of Open Access Journals
  • Pollution Abstracts
  • Publons
  • International committee of medical journals editors (ICMJE)
  • Google Scholar
  • Chemical Abstract
cheapjerseysupplychina.com - cheapjerseysupplychina Resources and Information.

cheapjerseysupplychina.com

This domain has expired. Is this your domain?
Renew Now!

Awards Nomination

Cancer Science & Pediatrics 2019: Newborns with hypoxic ischemic encephalopathy treated with hypothermia therapy using neonatal laminar flow unit - Jose M. R. Perez - Maternidade Sao Miguel, Casa de Saude de Guarulhos, Brazil.

Author(s): Jose M. R. Perez

Aim: The aim this trial was observational clinical the newborns with diagnosis of Hypoxic Ischemic Encephalopathy treated with hypothermia therapy in use of the Neonatal Laminar flow unit.

Hypoxic-ischemic encephalopathy (HIE) is associated with high rates of morbidity and mortality, and only recently has an effective treatment been developed to mitigate its sequelae. Moderate therapeutic hypothermia (TH) (core temperatures of 33oC–35oC) has been found in several randomized clinical trials to reduce mortality and improve neurodevelopmental outcomes in full-term neonates with moderate or severe HIE. TH can be administered using various techniques, but optimal use dictates meticulous control of targeted core temperature (usually assessed as rectal temperature), and thus servo-controlled devices have an advantage. Treatment is applied for 72 hours, and then gradual rewarming is performed at a slow rate. Rapid rewarming and hyperthermia should be avoided because they may be associated with neuronal damage and reversal of the benefits of TH. Long-term outcomes, at ages 6 to 8 years, correlate well with the benefits observed at 18- to 24-month follow-up. Although better than any alternative therapy currently available, the rates of mortality and morbidity remain high even when using TH. 2015 by the American Academy of Pediatrics. All rights reserved.

Share this article